Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

61509 1497862462HCLSReviewTaiwanJune2017.pdf
Energy Boardroom

New incontinence data could give Ipsen's Dysport a path to lucrative urology use

18.03.2014 / Fierce Pharma

Ipsen announced &quot;positive results&quot; in a Phase II trial of <span style="font-size: 13px;">Dysport in patients with urinary incontinence. That could put Ipsen&#39;s drug in line for more head-to-head competition with Allergan&#39;s Botox, which has successfully expanded into several medical uses.</span>

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: